Live news related to INVENTIVA stock (FR0013233012): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The latest financial news on INVENTIVA mainly cover M&A activity, earnings publications et analyst notes. The stock trades at €3,26 on Euronext Paris at the last update. This page lists the articles published on INVENTIVA stock to track the share price, company announcements and any item likely to influence market perception.
The biopharmaceutical laboratory Inventiva has requested a temporary halt of its stock trading on Euronext Paris on Tuesday morning, ahead of a financ…
On Tuesday, Inventiva released its Q1 2026 financial results, highlighting the critical trajectory of its cash reserves. The French biotech specializi…
Inventiva announces that its CEO, Andrew Obenshain, will participate in the 2026 Jefferies Global Healthcare Conference, which will take place from Ju…
Inventiva, a biopharmaceutical company specializing in the development of oral therapies for metabolic dysfunction-associated steatohepatitis (MASH), …
Inventiva announced on Tuesday the issuance of the second tranche of its structured financing, amounting to a gross total of €115.6 million (€108.5 mi…
Inventiva announced on Wednesday the recruitment of three new members to its executive team: Axel-Sven Malkomes as Chief Financial Officer, Susan Cole…
The stock of the biotech company from Lille gains 3.88% this Friday morning to €4.555, after having closed the previous day at €4.39. This rebound occ…
Inventiva experienced a significant decline on Tuesday, March 31, 2026, dropping 10.21% to €4.31 during the session, following the publication of its …
The French biotech company reports its 2025 results with a record cash position thanks to two major fundraising events. However, accelerated cash burn…
Inventiva's stock is up 3.2% at midday this Tuesday, trading at 5.48 euros in a positively oriented Parisian market. The French biotech has shown a re…
